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INJECTIONS of aliphatic nitrogen mustards (Boyland, Clegg, Koner, Rhoden
andWarwick, 1948 ; Stock, 1950) have proved of therapeutic value, but some-
times produce chnically undesirable side effects (Nabarro, 1950). The tris(2-
chloroethyl)amine (HN3), for instance, seemed very promising (Wilkinson and
Fletcher, 1947 ; Jiminez Diaz, Merchante, Perianes, Lopez and Puig, 1951), but
its use has beendiscouragedby thegreat risk ofthrombosis at the siteofinjection
(Rhoads, 1946 ; Nabarro, 1950). Clinical reports on the oral activitv of
V
an aromatic nitrogen mustard, NN-di(2-chloroethyl)P naphthylamine, R 4'8 (Haddow, Kon and Ross, 1948) and oftriethylene melamine, T.E.M. (Karnofsky,
Burchenal, Armistead, Southam, Benstein, Craver and Rhoads, 1951), therefore,
aroused muchinterest.
Human trials on the hazards of water contamination carried out by the
American Army Medical Centre indicated that aliphatic nitrogen mustardsmight
beabsorbedafter oraladministration : HN3in atotal dose of 15 to 18mg. per man
causedtransitory nausea, vomiting, anorexia, and the number ofW.B.Cs.dropped
to 2300 (Jager, Wintrobe, Ginzler and Gordon, 1943). It seemed of interest,
therefore, to see if aliphatic nitrogen mustards have an oral activity against
tumour-growth comparable to that of R 48 or T.E.M. Tests with these two com-
pounds and with three aliphatic nitrogen mustards, bis(2-chloroethAamine (nor
HN2), bis(2-chloroethyl)methylamine (HN2) and HN3, against transplanted
tumour are described in this paper.
TECHNIQUE.
Te8t tumour8.-Subcutaneous transplants of Walker careinosarcoma and of
mouse Sarcoma 37 were used. The Walker tumours were passages oftumour cell
suspension in dextrose, prepared by Craigie's mincer technique (Craigie, 1949)
and preserved at-70'C. (Craigie, 1949, 1952) at the laboratories of the Imperial Cancer Research Fund. The Walker tumour was transplanted by trocar and
Sarcoma 37 byCraigie's mincertechnique.
Test animal..-Two age groups offemale rats were used as hosts for the Walker
tumour :
(a) A group of 52 ± 3-6 g. body weight as recommended by Gye (personal
communication) ; (at this age theregular oestrus cycle has not yet developed and
individual variations in the growth rate of the tumours are comparatively small).
This group will be referred to as
" young
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(b) A group of 87 ± 5-6 g. body weight as recommended by Boyland (per-
sonalcommunication). For convenience these rats will be referred to as
" adult
rats.
Sarcoma 37 was grow-n in male mice of 18 to 22 g. bodyweight.
The animals were fed on Thomson's diet (19-2 per cent protein), the rats
receiving carrots in addition. Treatmentbegan one day afterimplantation ofthe
tumour and was continued on consecutive days, Sunday excepted. The mouse
sarcoma was treateddailyfor 7days. In the testsagainst the Walker tumour the
total dose was given over 7, 8 or 10 days, and aJso as a. single dose (Boyland,
Cleg, Koller, Rhoden and Warwick, 1948; Haddow, Kon and Ross, 1948).
Eleven to fifteen animals were used for test.
The water-soluble drugs were dissolved in distilled water immediately before
administration and given orally or intraperitoneally. The daily dose was given
in 0-4 ml. of distilled water per 100 g. rat. The oral dose was administered by
stomach-tube, and immediately afterwards 0-8 ml. of distilled water was passed
through the tube to ensu-re that the whole dose was washed into thl-, stomach.
R 48 was given in a single oral dose in arachis oil. Control animals received the
solvent by stomach-tube or remained untreated. The Walker tumours and Sar-
comata 37 were dissected 14 and 9 days respectively after transplantation, fixed
in Bouin's fluid and 70 per cent alcohol, dried between filter-paper, and weighed.
The difference inweight between control and treated tumours wasanalysed statis-
ticafly. The ratio, mean weight of control tumour divided by mean weight of
treated tumours, was used as the measure of the activity of the test compound.
Duplicate experiments were carried out at different dates.
RESULTS.
Int-raperitoneal treatment.
Given in approximately the maximum tolerated doses, b.oth HN2 and HN3
showed similar suppressive activity auainst the Walker tumour. The mouse
sarcoma, however,appeared to be more responsive to HN3. The Walker tumour
was significantly more affected by T.E.M. than by HN2 or HN3; the weight
ratio between controls and T.E.M. treated tumours was about 14 times that
between controls and tumours injected with the two mustards. When tested
against the mouse sarcoma, however, T.E.M. was significantly more active than
HN2, but not more active than HN3 (Table 1). The maximum tolerated dose
of nor HN2 was about 10 times that of HN2. When injected in these doses the
two compounds had similar activity against the Walker tumour (Table 11).
TABLE I.-Comparative Tumour-inhibitory Activity of Intraperitoneal Treatment
with Nitrogen Mustards and Triethylene Melamine.
Effect.
Daily dose Total dose A
Agent. (mg./kg.B.W.). (mg./kg.B.W.). Test tumour. Signif. Ratio. (P.).
HN2 hydrochloride 0-12 1-20 Walker 7- 2 <0_01
0-50 3- 50 Sarcoma 37 2- 2 0.01
0-50 3-50 2-3 <0.01
HN3 hydrochloride 0-10 1.00 Walker 7-8 <0.01
0-50 3-50 Sarcoma 37 7-5 <0.01
Triethylene melamine 0-16 1-60 Walker 104-0 <0.01
0-25 1-75 Sarcoma 37 4-6 0.01264 0. PECZENIK
Themonofunctionalethyleneiminein atotaldoseof IOmg. perkg. wasinactive.
NN-bis(2 chloroethyl)p-phenylene diamine hydrochloride in a total dose of 4 mg.
perkg. hadsignificant activity (ratio 5-4; P<0-01).
Oral treatment.
(a) 1'est animal-sfed ad libitum.-The three aliphatic nitrogen mustards when
administered orall also retarded tumour-growth. The maximum tolerated oral
dose was about twice the maximum tolerated intraperitoneal dose. Using these
doses, both oral and parenteral treatment produced similar effects against the
Walker tumour (Table 11). The oralactivity seeme'd to be influenced by the dis-
tribution of the total dose ; the weight ratio between control and HN2-treated
tumours became moresignificant when the total dose was divided over 7 instead of
over IO da-ily doses. Boyland, Cleg, Koller, Rhoden and '"Tarwick (1948) found
that the parenteral activitv of nitrogen mustards increased when the total dose
was given as a single injection. When given in a single oral do the effect of
HN3 was negligible, whereas the activity of HN2 and nor HN2 seemed to be in-
creased to a certain extent. The oral activity of nor HN2 seemed at least equal
to that of HN2, and more pronounced than that of HN3, but even the highest
weight ratios between control-tumours and those treated with the ahphatic com-
pounds were only about one-quarter of the ratio recorded after treatment with
R 48 (Table II). The other aromatic nitrogen mustard tested, NN-bis(2 chloro-
ethyl)p-phenylene diamine hydrochloride, when given as a single oral dose of 4
mg. per kg. was inactive. Larger doses were active but toxic.
T.E.M., though strikingly suppressive after intraperitoneal injection, retarded
thegrowth ofthe Walker tumour to anegligible extent when givenorally. When
the maximum tolerated dose of 4 mg. per kg. rat was divided over 10 days, no
activity was seen. When the same amount was given in a single dose, tumour-
growth wasshghtly butprobablysignificantly retarded.
TABLE II.-Tumoitr inhibitory Activity of Nitrogen Mu8tard8 and Triethylene
Melamine Admini,9tered to Young Rat8 (52 ± 3-6 g.).
Effect.
Daily dose Total dose
A
Agent. Route. (xng./kg.B.W.). (xng./kg.B.W.).
r
Signif. Ratio. (P.).
HN2 hydrochloride Intrap. 0-12 .1-2 7
- 2 <0.01
Oral 0-28 2-8 5-4 <0-02>0.01
0-40 2-8 11.9 <0_01
2-80 2- 8 7-6 <0.01
nor HN2 hydrochloride
. Intrap. 1-20 12-0 8-1 <0.01
Oral 2-80 28-0 10-2 <0.01
28-00 28-0 12-1 <0.01
HN3 hydrochloride
. Intrap. 0-10 1.0 7-8 <0-01
Oral 0-20 2-0 6.5 <0-01
0-20 2-0 6-6 <0.01
2-00 2-0 2-3 0-02
2-00 2-0 2-4 <0-02>0.01
R 48 100-00 100.0 52-4 <0.01
Triethylene melamine Intrap. 0-16 1-6. .104-0 <0.01
Oral 0-20 2.0 2-0 0-20
0-40 4-0 1-4 0-20
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(b) Fasting test aninmls.-As show-n in Table IT, a single oral dose of T.E.M.
or HN3 was almostinactive, but the same dosegiven to tumour-bearers which had
beenkeptfastingfor 22 or 32 hours before and 4 hours after treatment wassignifi-
cantly active. This dose, though tolerated by non-fasting rats, was toxic to the
fasting animals (Table III).
TABLE III.-InfluenceofFasting on the OralActivityofSingle Doses ofTriethylene
Melamine and Nitrogen Mustard (Young Rats of 50 ± 3-7 g. Body-weight).
Effect.
t A-
Ratio. Signif.
(P.).
3- 6 <0-02>0-01
27
-0 <0-01
2-4 <0-02>0-01
8- 6 <0-01
Dose
(mg-/kg.
B.W.).
Test No. of Changein
animal. survivors. ody-weight
M.
Agent.
Triethylene melamine
HN3 hydrochloride
.
4-0 Fed
4-0 . Fasting
2-0 Fed
2-0 . Fasting
. 12/12
8/12
12/12
12/14
+52
+40
+31
+33
Influence of the age of the test animals.
All the tests described above were carried out on young rats. Some furth'er
tests wereperformed with the adult group to find whether the permeability ofthe
gastro-intestinal mucosa decreases with maturation. Some of the results varied
with the age-grou'p. After oral treatment with HN3 the weight ratios between
control and treated tumours were greater in the young rats. In adult rats 2 mg.
per kg. retarded tumour-growth slightly but significantly; 2-8 and 3-2 mg. per
kg. produced an effect similar to thatproduced in the young animalsby 2 and 2-8
mg. per kg. respectively. It is doubtful whether these differences were due to a
greater permeability of the gastro-intestinal mucosa in the young rats, for after
oral treatment with HN2 the ratios were greater in the adult rats, but not in the
young rats (Table IV). Moreover, a difference in response between the two age
TABLEIV.-Tumour-inhibitoryActivityof NitrogenMU8tards andTriethylene Mel-
amine Admini8tered to Young and Adult Rat8.
Effect Effect
Dailydose
Route. (mg./kg.
B.W.).
Total dose
(mg-/kg. r-
B.W.). F
2-8
I 2-8 . I
young rats. adult rats.
A
latio. Signif. Ratio. Signif.
(P.). (P.).
5-4 <0-02>0-01. 15-6 <0-01
12-1 <0-01 25.3 <0-01
15-6 <0-01
7-8 <0-01 1-7
8-6 <0-01
6-5 <0-01 2-9 <0-02>0-01
6-6 <0-01 3-5 <0-01
2-3 0-02 3-2 <0-01
2-4 <0-02
Agent.
HN2 hydrochloride
HN3 hydrochloride
. Oral .
VP
. Intrap.
.
19, I
Oral .
0- 28
0-40
0-40
0-10
0.10
0- 20
0-20
2-00
2-00
0- 25
0-40
0-40
0-40
0-16
0-40
2- 8
1.0
1.0
2- 0
2-0
2- 0
2-0
2- 5
2- 8
2- 8
3- 2
1-6
4-0
9 9
9 p
ilt
5- .
9 9
9 9
Triethylene melamine . Intrap..
Oral .
4-4 <0-01
. 7- 2 <0.01 . 13-9 <0.01
. 14- 3 <0.01
14-0 <0.01
. 104-0 <0-01 .346-0 <0.01
1-4 0-2 . 1-6 0.1
groups was also found after intraperitoneal treatment : T.E.M., injected in a
tota-I dose of 1-6 mg. per kg., suppressed tumour-growth even more strikingly in266 0. PECZENIK
the adult group ; the ratio was about 3 times that recordedin the young animals--
Seven tests only were performed in duplicate, six of them against the Walker
tumour. In the three tests with the young rats the duplicat-e results agreed,
whilst in the three tests carried out with the adult rats the duplicates agreed in
two but disagreed in the other (intraperitoneal treatment with HN3). In view
of the smaller numbee of tests carried out in duplicate one cannot exclude the
possibility that the difference in response between the two age-groups may
represent only variations in susceptibility to the tumour-inhibitors between the
individual batches of animals.
Bromine 8ub8titUte8.
In the case ofhaloarvlalk amines with little or no tumour-inhibitoryactivity,
it was found that the replacement of chlorine by the more reactive bromine pro-
duced active compounds (Haddow, Kon and Ross, 1948). Bromine substitution
in HN2 and HN3, however, did not increase the activity against the Walker
tumour ; in fact, given in the doses in which the chlorine compounds were active
the two brominecompounds showed noinhibitoryactivity whatever.
Toxicity of the nitrogen mustard8and triethylene melamine in tumour-bearer8.
Givenorally, R 48 was tolerated in a dose about 36 and 50 ti'mes the maximum
tolerated doses of HN2 and HN3 respectively. The maximum tolerated oral
dose of nor HN2 was about 10 times larger than that of HN2 and 14 times larger
than that of HN3 (Table 11). The therapeutic ratio of HN2 and HN3, whether
the drugs weregivenintraperitoneally ororally, seemed as low as 2, or even lower.
As estimated from the death-rate, HN2 and HN3 were more toxic to tumour-
bearing than to normal rats. HN2, for example, in a daily intraperitoneal dose
of 0-28 mg. per kg. was tolerated by normal rats for 18 days but proved toxic
to tumour-bearerrs within 10 days. Oral treatment with HN3 in a daily dose of
0-28 mg. perkg. was tolerated by normal rats for 14 days, whilst 0-25 mg. per kg.
was toxic to tumour-bearers after 10 days. Toxicity was somewhat unpredic-
table in tumour-bearers: in one test, for instance, injections of HN2 in daily
doses of 0-27 mg. perkg. were tolerated, whilst in two others 0-2 mg. per kg. was
toxic. HN3 given orally in a total dose of 3-2 mg. per kg. was tolerated by one
batch of tumour-bearers, though individuals from other batches were killed by
2-5 mg. per kg.
Goldin, Goldberg, Ortega and Schoenbach (1949) demonstrated a similar varia-
tion in mice bearing Sarcoma 180; in four batches injected with HN2 (7-5 mg.
perkg. mouse)mortality varied from zero to 25 per cent. The young rats were at
least as resistant totoxicity as were theadults, and in some instancesthey seemed
even more resistant. For instance, oral treatment with HN2 in 7 dailv doses of
0-4 mg. perkg. was toxic to adult but toleratedby young tumour-bearers.
Effect ofnitrogen mustard8and triethylene melamine on body-weight.
The tumour-inhibitory effect of the agents investigated was frequently asso-
ciated with inhibition of somatic growth. In some instances, more frequent in
the adult than in the young rats. there was even loss of mean body-weiglit.
Animals treated orally with R 48, T.E.M. or nor HN'2 gained in bodyweight con-
siderably more than those treated with HN2 or HN3. The stunting effect of the267 INHIBITION OF TUMOUR-GROWTH BY NITROGEN MUSTARDS
drugs appeared to be influencedby the distribution ofthe dose. Tumour-bearers
which had received nor HN2 in a single oral dose (28 mg./kg.) gained in mean
body-weight only 22 per cent less than the controls, but when the total dose was
divided up over 10daily doses, the growth rate of the treated rats was only about
one-quarter of that of the controls. Similar differences were observed after oral
treatment with HN2 or HN3. The maximum tolerated dose prevented body
growth when divided into 10 daily doses, but allowed some gain in mean body-
weight (28 to 52 per cent) whengiven in asingle dose. Compaiison ofthe effects
of maximum tolerated doses given in the same distribution suggests that oral
treatment suppresses somatic growth less than do injections.
Influence ofadrenocortical extract or urethan on toxicity of HN3.
The addition of adrenocortical extract (Kucharik and Telbisz, 1945) or ure-
thane (Anslow, Karnofsky, Jager and.Smith,. 1947)-has been-rep-orted-to reduce
the toxicity of mustards. An attempt at reducing the toxicity of HN3 in this
way was unsuccessful. The experiment is described here because it has been sug-
gested that urethanepotentiates the effect ofnitrogen mustardsclinically. Three
groups of adult bearers of Walker tumour received HN3 orally in a daily dose of
0-4 mg. per kg. rat for 8 days. One group received in addition intraperitoneal
injections of 25 mg. of urethane daily, a dose of urethane whichper8eisknown to
be inactive against the Walker tumour. Another group received unstandardized
adrenocortical extract (Eucortone) intraperitoneally, I ml. (corresponding to 75
mg. offresh gland) being given daily at the same time as the HN3. The toxicity
of HN3 was not reduced by these collateral treatments; some animals died, and
the survivors lost more weight than those which had received HN3 alone. The
weightratiobetweencontrol tumours and those treated with HN3 + urethane(22)
was greater than that between controls and those treated with HN3 alone (14),
but the difference was statistically not quite significant (P<0-05>0-02) and does
notprove apotentiatingeffect.
DISCUSSION.
Theinbibition ofgrowth ofthe Walker tumourproducedby oral adminstration
ofaliphaticnitrogen mustards wascomparable to thatproducedbyadministration
ofthesereagentsparenterally. Nor HN2appeared to be at least as active as and
at the same time less toxic than HN2 or HN3. Oral treatment with triethylene
molamine, on the otherhand, produced no significant inhibition oftumour-growth
unless given to fasting rats, but to these a dose which was tolerated by fed rats
proved toxic. This result is not at variance with those of previous workers.
Hendry, Homer, Rose andWalpole (I951)foundtriethylene melamineorally active
against the Walker tumour, but the figures published by these authors show that
the oral doses were I0 to 20 times greater than those which they had found
markedly active after injection. Paterson and Boland (1951) found the haema-
tological response to oral doses less predictable than to parenteral treatment.
Clinical trials by Karnofsky, Burchonal, Armistead, Southam, Benstein, Craver
and Rhoads (1951) showed that the drug reacts readily with organic material in
the stomach and is therefore almost inactivated unless given during fast.
As described above, treatment began one day after implantation of the test
tumours. Nevertheless, the growth rate of the treated transplants differed little268 0. PECZENIK
from that of the controls during the first few days
- Inhibition of the Walker
tumour became manffest during the second week, suggesting that the agents clid
not influence the
" take
" of the transplants.
Thetherapeutic ratios ofHN2 and HN3 areprobably not lar er after oral than
after intraperitoneal administration.
Innon-tumour-bearingratsfedwithHN3, Roberts(1952,personalcommunica-
tion) found changes in the intestine very similar to those described by several
authors after injections of nitrogen mustards (Selye, 1950). In view of this
finding, it is worthnoting that most of the tumour-inhibition shown in this paper
was associated with significant suppression of somatic growth, whether the drugs
were givenintraperitoneally or orally. That held true even when the net weight
(body-weight minus tumour-weight) was considered instead of the gross weight.
Thus the question arises to what extent the tumour-inhibition recorded after oral
administration ofthe agents was due to a specific effect or to starvation. Walpole
(1951) has fo-und 40 per centgrowth-inhibition ofuntreatedWalker tumours when
somaticgrowth waspreventedbyunderfeeding. Ifthis 40percentoftheobserved
tumour-inhibition is deducted from the figures in Tables I to IV, the maximum
.tolerated oral dose of HN3 would appear to be inactive in adult tumour-bearers
(TableIV) whilst thesignificance ofthe other results remainsunchanged. It may
beassumed, therefore, that the retardation oftumour-growth described above was
mainly due to other causes than starvation. This view issupportedbythefinding
that the suppression oftumour-growth after asingle oral dose ofR 48 or nor HN2
was not associated with suppression of somatic growth. Moreover, -whilst effects
,on tumour-growth were similar, effects'on body-growth were more pronounced
afterintraperitoneal than after oral treatment. On the otherhand, Elson's (I951)
-recent work suggests that specific tumour-inhibition may be
" one manifestation
of a more generalgrowth-inhibiting action". In.14-day tests, tumour-inhibitors,
including radi.tion, proved more active against the Walker tumour on a 5 per
cent than on a, 20 per cent protein diet. Most of the animals on both diets lost
weight during the treatment, and the ratio between theweight losses in rats with
the 20 per cent and the 5 per centprotein diet was almost the same as the ratio of
the degrees of tumour-inhibition. According to Houck, Crawford, Bannon and
Smith (1947), animals treated with nitrogen mustards lose body weightbyloss of
protein and water. The rats under theseexperiments, therefore, though fed with
ahighprotein diet (19-2 percent), lostprotein. Loss ofprotein mayalsointensify
the effect ofinhibitors on tumour- and body-growth. According to Elson (1951),
as an initially large dose of an inhibitor is gradually reduced, the animal will
recover from the inhibitory action quicker than the tumour will, and the latter
maycompletely regress under high protein diet. It may well be that in those
my experiments in which the drug was given in a single dose the loss ofprotein
ceasedin time to aRow the animal to recover itsgrowth-rate whilsttumour-growth
remained retarded.
SUMMARY.
Administered intraperitoneally in about maximum tolerated doses, nor HN2,
HN2 and HN3 had approximately equal activity against the Walker carcino-
sarcoma, although aaainst the Sarcoma 37, HN3 was more active than HN2.
TheWalker tumour was significantly more affected bytriethylene melamine than
by the aliphatic nitrogen mustards. When tested against the mouse sarcoma,INHIBITION OF TUMOUR GROWTH BY NITROGEN MUSTARDS 269
however, triethylene melamine was more active than HN2, but not more active
than HN3.
R 48, nor HN2, HN2 and HN3given orally in about maximum tolerated doses
had an inhibitory action against the Walker tumour similar to that following
intraperitoneal injection. R 48 was at least 4 times as active as the aliphatic
amines. Bis(2 chloroethyl)p-phenylenediamine was active after intraperitoneal
but inactive after oral administration.
Bromine substitution in HN2 and HN3 seemed to cause loss of activitv.
Triethylene melamine given orally was practically inactive in the non-fasting
rat, whereas the same dose given to the fasting animal had marked activity but
was toxic.
Tumour-bearing rats tolerated R 48 and nor HN2 in dosesrespectively 36 and
10 times the maximum tolerated dose of HN2. The toxicities of HN2 and HN3
were somewhat unpredictable and greater than in normal rats, whether the drugs
wereinjected orgivenorally. Anattempt atreducing thetoxicitybythe addition
ofadrenocortical extract or urethan proved unsuccessful.
I am indebted to E. Boyland, W. A. Broom, J. Craigie, Sir J. Drummond,
W. E.Gye, A. Haddow, P. C. Koller and C. Chester Stock for theirhelp andadvice
during the course of this work.
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